Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2020-02-14 Major Shareholding Noti…
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
CONSONANCE CAPITAL MANAGEMENT LP
Major Shareholding Notification
2020-02-14 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-13 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 11, 2020. It includes a press release about ADMA Biologics receiving an award, filed as an exhibit. The content is a short announcement of an event rather than a detailed financial report or earnings release. The document length is 3104 characters, which is relatively short and consistent with an 8-K announcement. There is no substantive financial data or detailed management discussion. Therefore, this is a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2020-02-11 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically details the completion of a sale of common stock shares under a shelf registration, including gross proceeds and underwriting details. There are no financial statements or comprehensive financial data presented, only an announcement of a financing event. The document length is 3614 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2020-02-11 English
Regulatory Filings 2020
Regulatory Filings
2020-02-11 English
Director's Dealing 2020
Director's Dealing
2020-02-11 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.